PCI Biotech and MDimune announce research collaboration agreement

Posted: January 5, 2022 at 2:29 am

Oslo, Norway and Seoul, South Korea 5 January, 2022 – PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company and MDimune Inc. (“MDimune”), a private South Korean biotech company developing innovative drug delivery technologies for modifying cellular and disease processes in many areas of human disease, today announced a preclinical research collaboration that would offer several opportunities for future development.

Original post:
PCI Biotech and MDimune announce research collaboration agreement

Related Posts